The near future looks very different in terms of what will be spent on specialty medications as opposed to traditional drugs, according to Express Scripts’ 2011 Drug Trend Report. The company forecasts 20 percent growth for specialty medications from now to 2014. The study, based on random samples of pharmacy data of 4 million people, cites three reasons:

  • For the first time, HIV and transplant medication categories were considered when estimating the growth of specialty drug costs, and they are covered by pharmacy benefits.
  • Plan sponsors are moving away from buy-and-bill payment arrangements with doctors as specialty drug coverage migrates from the medical to the pharmacy benefit.
  • There’s been an onslaught of approvals of self-injected drugs, which usually fall under the pharmacy benefit.

Help may be on the way with the introduction of some biosimilars that could slow the cost increases beyond 2014.

All percentage changes on this page are per member, per month for members in the PBM’s commercial business.

Spending on specialty drugs to rise

Most costly specialty therapy classes

Inflammatory conditions (including rheumatoid arthritis, psoriasis, lupus, and gout), multiple sclerosis, and cancer have been the most expensive specialty drug categories for many years, and they will continue to top the list through 2014. They will be followed by drugs for HIV, a new category. Drugs for hepatitis C are expected to be in fifth place by next year.

Meanwhile, for the first time since Express Scripts started publishing its Drug Trend Report in 1997, the per-member, per-month cost of traditional medications will dip this year. “We expect [costs] to rise only modestly in 2013 and 2014, fueled primarily [by] increases in overall drug utilization.” The reason is patent expirations. “Cost per unit is expected to decline in 2012 and 2013 — due not only to the availability of more generic medications, but also to continued reductions in the cost per fill for generics.”

Historic low costs for traditional medications

Source: 2011 Drug Trend Report, Express Scripts, April 2012.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.